We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Response Genetics Enters Next Generation Sequencing with Lung Cancer Panel from Knight Cancer Institute

By LabMedica International staff writers
Posted on 28 Apr 2014
Print article
Response Genetics, Inc. (Los Angeles, CA, USA) has entered an exclusive commercial agreement with the Knight Diagnostic Laboratories (Portland, OR, USA), part of the Knight Cancer Institute at Oregon Health & Science University (OHSU), for a proprietary next generation sequencing (NGS) panel for lung cancer. The panel provides full sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots.

The collaboration will leverage Response Genetics' national sales force and expects to begin marketing the panel immediately. With this panel, Response Genetics now offers oncologists and patients analyses of actionable genetic markers across 6 different tumor types and 4 different testing modalities. All of these tests will leverage Response Genetics' state-of-the-art reporting that gives physicians easy to understand, actionable information for patients.

"We are excited to announce this strategic relationship with the Knight Diagnostic Laboratories as it marks the entry of Response Genetics into next-generation sequencing," said Thomas A. Bologna, Chairman and CEO of Response Genetics; "We believe Knight Diagnostic Laboratories' NGS lung cancer panel represents the best in class and will further strengthen our unique Academic Profile for lung. The two together make for a differentiated product offering that includes gene mutation, amplification, and translocation data, as well as RNA expression-based data. We believe the use of multiple technology platforms enables us to provide truly comprehensive, actionable information for cancer therapy selection. Moreover, our approach offers physicians a choice of options so that they can optimize turnaround time, cost, and other considerations on a patient-by-patient basis, rather than accepting a singular methodology or a ‘one size fits all’ test. The addition of NGS to our portfolio further illustrates our patient-centric commitment to therapy selection based on the unique molecular characteristics of each patient's tumor."

"The collaboration with Response Genetics allows the Knight Diagnostic Laboratories an opportunity to offer our next-gen lung panel nationwide," said Christopher Corless, MD, PhD, professor of Pathology and Chief Medical Officer of the Knight Diagnostic Laboratories. "With the reach of Response Genetics' commercial operation, we can maximize patient access to a thoughtfully curated panel of actionable markers. The selection of Knight Cancer Institute by Response Genetics, one of the leading commercial reference laboratories in the molecular diagnostic space, validates the years of effort that we put into the development of our innovative offering. Together we can deliver significant clinical value with a very favorable cost profile."

Related Links:

Response Genetics
Knight Diagnostic Laboratories 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.